Pricing mechanics · Tirzepatide
Flat versus dose-tiered pricing, over a titration year
Two programs can advertise the same monthly price and cost hundreds of dollars apart over a titration year. The difference is whether the price moves when the dose moves — and it is the single most consequential thing a GLP-1 price comparison can get wrong.
Two pricing models
A dose-flat program charges one price at every dose. You pay the same at 2.5 mg as at 15 mg, so titrating upward costs nothing extra. 16 of the 27 rankable tirzepatide programs in this database work this way.
A dose-tiered program charges more as the dose rises. Its advertised figure almost always describes the bottom of the ladder — the dose you spend four weeks on before your first increase.
LillyDirect (Zepbound) is a worked example from the database: $299 a month at 2.5 mg rising to $449 at 7.5 mg. That is $150 more per month at the top of the ladder than at the bottom, or $1,800 across a year if you settle high.
By contrast NexLife, the cheapest dose-flat tirzepatide program in the database, holds at $169 a month at every dose on the ladder — a straight line rather than a staircase.
The arithmetic over a titration year
Consider a standard ramp: four weeks at 2.5 mg, four at 5 mg, four at 7.5 mg, then settling at 10 mg for the rest of the year. On a flat program the annual cost is simply twelve times the one rate. On a tiered program it is three cheaper months followed by nine at the settled rate — genuinely lower than twelve times the maintenance price, but higher than twelve times the advertised starting price.
This is why this site quotes every figure at the maintenance dose. It is the only point on the ladder that describes most of your year. Quoting the starting dose flatters tiered programs; quoting an average flatters nobody accurately.
Which model suits whom
If you expect to settle at a high dose, flat pricing is worth more than the headline gap suggests, and it removes the incentive problem where the program you pay makes more money each time your dose rises. If you expect to respond at a low dose and stay there, a tiered program can genuinely be cheaper — but you are betting on your own response before you have started.
The asymmetry matters: a flat program's worst case is that you overpay slightly at low doses. A tiered program's worst case is an open-ended increase you did not price when you signed up.
The programs that publish neither
10 of the 27 rankable tirzepatide programs do not publish a price at every dose. Some publish a starting price and nothing else; some publish a maintenance price and nothing else. In every one of those cases the honest answer to "what will I pay at 7.5 mg" is that the company has not said, and this site leaves the cell blank rather than filling it in. Ask before you enrol, and get the answer in writing.
Questions
What is flat-rate GLP-1 pricing?
A program that charges the same monthly price at every dose, so titrating upward does not increase what you pay. 16 of the 27 rankable tirzepatide programs in this database price this way.
Is flat pricing always cheaper?
No. If you settle at a low dose, a dose-tiered program can be cheaper. Flat pricing is worth most to people who titrate to the top of the ladder, and its real advantage is certainty: you know your year-two cost on the day you sign up.
Why do comparison sites get this wrong?
Because most reduce a program to a single number, and a single number cannot express a price that changes with dose. A flat-rate program and a tiered program quoting the same headline are not the same product.